A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State

Inclusion Criteria: * Participants with age greater than or equal to (\>=) 18 years with either unresectable Stage IIIC or Stage IV metastatic melanoma positive for the BRAF V600 mutation, or other malignant tumor types that harbor a V600-activating mutation of BRAF * Eastern Cooperative Oncology Group Performance Status 0 to 2 * Life expectancy \>=12 weeks * Adequate hematologic and end organ function obtained within 2 weeks prior to first dose of study drug * Female participants of childbearing potential and male participants with partners of childbearing potential must agree to always use two effective methods of contraception including at least one method with a failure rate of \<1% per year during the course of the study and for at least 6 months after completion of study treatment * Negative serum pregnancy test within 7 days prior to commencement of dosing in women of childbearing potential * Absence of any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule Exclusion Criteria: * Prior treatment with vemurafenib or other BRAF inhibitor within 42 days of Study Day 1 of Period A * Allergy or hypersensitivity to components of the vemurafenib formulation * Experimental therapy within 4 weeks prior to first dose of study drug treatment on Study Day 1 of Period A * Major surgical procedure or significant traumatic injury within 14 days prior to first dose of study drug treatment o…